ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: 50 years Female

Specimen Collected: 13-Sep-23 11:10

Factor 13 1:1 Mix	**Received: 13-Sep-23 11:10**		**Report/Verified: 14-Sep-23 10:22**
Procedure	**Result**	**Units**	**Reference Interval**
Factor XIII,1:1 Mix	**No Lysis** * f1		

Factor 13 Qualitative, Reflex to 1:1	**Received: 13-Sep-23 11:10**		**Report/Verified: 14-Sep-23 10:22**
Procedure	**Result**	**Units**	**Reference Interval**
Factor XIII,Qualitative	**Lysis** *		[No Lysis]

Result Footnote

f1: Factor XIII, 1:1 Mix

Clot lysis was observed in the qualitative factor XIII screening test. Clot lysis was not observed when the test was repeated using a 1:1 mix of patient plasma and pooled normal plasma. This pattern suggests severe factor XIII deficiency (less than approximately 1% of normal activity).

False-positive results (lysis) can be caused by heparin (therapy with unfractionated or low molecular weight heparin or contamination from a line), decreased or abnormal fibrinogen, increased fibrinolysis (inherited or acquired fibrinolytic disorders), fibrinolytic drugs, or other factors that affect clot structure or stability. Interpretation of these results requires correlation with clinical information and the results of additional laboratory testing. Quantitative factor XIII testing (Factor XIII Activity test code 2006182) is recommended for confirmation.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab